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Background: Since the majority of melanomas eventually become resistant and progress, combining selective BRAF
inhibitors (BRAFi) with immunotherapies has been proposed to achieve more durable treatment responses. Here, we
explored the impact of selective BRAFi on the hosts’ immune system.
Patients and methods: Clinical data, whole blood counts (WBC) and serum lactate dehydrogenase (LDH) of 277
vemurafenib- and 65 dabrafenib-treated melanoma patients were evaluated. The frequency and phenotype of lymphocyte
subpopulations were determined by ﬂow cytometry while T cell cytokine secretion was measured by multiplex assays.
Results: Progression-free survival (PFS) as well as overall survival (OS) were similar in patients treated with either BRAFi.
High pretreatment LDH was associated with shorter PFS and OS in both groups. During therapy, peripheral lymphocytes
decreased by 24.3% (median, P < 0.0001) in vemurafenib-treated patients but remained unchanged in dabrafenib-
treated patients (+1.2%, P = 0.717). Differentiation of peripheral lymphocytes of vemurafenib-treated patients showed a
signiﬁcant decrease in CD4+ T cells (P < 0.05). Within CD4+ T cells obtained during treatment, an increase in
CCR7+CD45RA+ (naïve) and a decrease in CCR7+CD45RA− (central memory) populations were found (P < 0.01 for
both). Furthermore, secretion of interferon-γ and interleukin-9 by CD4+ T cells was signiﬁcantly lower in samples obtained
during vemurafenib treatment compared with baseline samples.
Conclusion: While both compounds have comparable clinical efﬁcacy, vemurafenib but not dabrafenib decreases
patients peripheral lymphocyte counts and alters CD4+ T cell phenotype and function. Thus, selective BRAFi can signiﬁ-
cantly affect patients’ peripheral lymphocyte populations. Fully understanding these effects could be critical for success-
fully implementing combinatorial therapies of BRAFi with immunomodulatory agents.
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introduction
Despite the introduction of selective BRAF inhibitors (BRAFi) such
as vemurafenib and dabrafenib, metastatic melanoma remains a
disease with poor prognosis [1]. High rates of initial responses in
melanoma patients treated with selective BRAFi have been observed,
but tumors eventually become resistant and complete responses are
rare [1]. In contrast, immunotherapies, e.g. with anti-CTLA4 and
anti-PD-1 antibodies, can induce durable responses in a small sub-
group of melanoma patients [2, 3]. Although a phase I trial employ-
ing vemurafenib in combination with ipilimumab, an anti-CTLA4
antibody, had to be discontinued due to severe liver toxicity [4],
combining selective BRAFi and immunotherapies might prove ben-
eﬁcial in avoiding the shortcomings of the individual agents [1].†These authors contributed equally.
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BRAFi impair cancer cell growth by decreasing MAPK
pathway signaling. This pathway is relevant also in downstream
T cell receptor signaling [4], implying that selective BRAFi
could potentially alter immune responses and anti-tumor im-
munity in humans. Several in vitro studies have reported that
analogs of vemurafenib do not inhibit human lymphocyte func-
tion [4, 5]. Comin-Anduix et al. [4] did not observe induction of
apoptosis or inhibition of cytotoxicity in human T cells by
vemurafenib in vitro. Similar results were obtained by Boni et al.
[5] who found no impact of selective BRAFi on proliferation
and viability of T cells. In this in vitro study, recognition and
killing of tumor cells by T cells speciﬁc for melanoma differenti-
ation antigens (MDA) was enhanced by selective BRAFi treat-
ment, which up-regulated MDA expression [5]. Analysis of
tumor biopsies obtained during treatment with dabrafenib or
vemurafenib also showed an increase in inﬁltration of melanoma
metastases by human CD4+ and CD8+ T cells and the presence of
CD8+ T cells was found to be associated with the reduction in
tumor mass [6]. For dabrafenib, Hong et al. [7] showed that com-
position and functionality of patients’ lymphocytes remained un-
affected by treatment. In summary, lymphocyte function seems to
be unaffected by selective BRAFi, while antigenicity of melanoma
cells is increased.
Whereas we reported a decrease in immunosuppressive myeloid
cells in patients with advanced melanoma during vemurafenib
therapy recently [8], no data following patients’ lymphocytes during
vemurafenib treatment have been published yet. In this study,
we explored the effects of selective BRAFi on the human immune
system by analyzing T cells, B cells and natural killer (NK) cells
as well as neutrophils. The retrospective analysis of clinical data
from a large cohort of patients treated with selective BRAFi
showed striking differences in the effects of vemurafenib and
dabrafenib on patients’ peripheral lymphocytes.
materials andmethods
clinical data and blood samples
Patients enrolled in this study started treatment with either vemurafenib or
dabrafenib between May 2010 and March 2013 in 10 DeCOG (Dermatologic
Cooperative Oncology Group) skin cancer units. After determining BRAF
status, treatment was chosen based on availability. Whole blood counts
(WBC) were carried out within 4 weeks before starting BRAFi treatment in
277 melanoma patients receiving vemurafenib and in 65 patients receiving
dabrafenib and were repeated every 4–6 weeks during therapy. For our ana-
lyses, the nadir of lymphocytes within the ﬁrst 12 weeks of treatment with
either BRAFi was used. Peripheral blood mononuclear cells (PBMC) were
obtained from 18 melanoma patients treated with vemurafenib (Stage IV,
AJCC 2009 [9]) after written informed consent with local ethics approval.
Clinicopathological characteristics are listed in Table 1. BRAF status in mel-
anoma tissue was determined by Sanger sequencing or allele-speciﬁc PCR.
antibodies
The following ﬂuorochrome-labeled monoclonal antibodies (mAbs) pur-
chased from Beckman Coulter (Brea, CA) were used: anti-CD8-APC-Alexa
700, anti-CD4-FITC and PECy7, anti-CD3-PECy5, anti-CD19-ECD, anti-
CD45-FITC as well as anti-CD56-PE. Anti-CD45RO-Alexa Fluor 700®,
CD69-PerCP/Cy5.5, CD8-APC, CD45RA-PECy7 and anti-CCR7-PE were
purchased from Biolegend (San Diego, CA). Appropriate isotype controls
were purchased from Beckman Coulter and BD Pharmigen (Heidelberg,
Germany).
whole blood counts
WBC were carried out on clinical grade automated hematology analyzers,
e.g. XE-5000 (Sysmex, Norderstedt, Germany).
isolation of PBMC
PBMC were isolated by density gradient centrifugation using Biocoll
(Biochrom, Berlin, Germany) from heparinized venous blood and stored in
liquid nitrogen until usage. In some samples, the number of PBMC recov-
ered was too small to conduct all phenotypic and functional studies.
staining for ﬂow cytometry
First, cells were incubated with Aqua Viability Dye (BD, Detected on FL-10)
for 30 min at room temperature. After washing, samples were surface
stained, acquired and analyzed as described [8].
Frequencies of CD3+CD4+ T cells, CD3+CD8+ T cells, CD19+ B cells and
CD3−CD56+ NK cells were determined after gating on lymphocytes deﬁned
by their forward and side scatter properties (FS/SS). Total numbers were
then calculated using absolute lymphocyte counts measured in WBC.
Table 1. Clinicopathological characteristics of patients enrolled in
this study
Vemurafenib
(n = 277)
Dabrafenib
(n = 65)
P-value
Age (years),
median (range)
56 (21–84) 51 (20–79) 0.069
Sex (%) 0.275
Male 164 (59.2) 41 (63.1)
Female 113 (40.8) 24 (36.9)
Stage (AJCC 2009)
(%)
0.55
Unknown 1 (0.4) 0
Stage III 5 (1.8) 0
Stage IV 271 (97.8) 65 (100)
M stage (%) 0.187
Unknown 1 (0.4) 0
M1a 21 (7.7) 5 (7.7)
M1b 31 (11.4) 2 (3.1)
M1c 218 (80.4) 58 (89.2)
LDH (U/l) before
therapy, median
(range)
271 (137–9555) 218 (135–2033) 0.034
Number of
previous
therapies,
median (range)
1 ( 0–6) 1 (0–5) 0.931
Lymphocytes per
nl before
therapy, median
(range)
1.27 (0.16–4.81) 1.4 (0.31–4.03) 0.225
PFS (weeks),
median (range)
21.3 (0.4–167) 21.0 (3.6–142) 0.98
OS (weeks),
median (range)
44.1 (3–167) 46.3 (11–142) 0.84
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magnetic cell sorting
From PBMC, CD4+ T cells and CD4− cells were isolated by magnetic bead-
based separation (MACS technology, Miltenyi, Bergisch-Gladbach, Germany)
according to the manufacturer’s instructions. Purity, as determined by ﬂow
cytometry, was ≥97%.
cell culture
After thawing, PBMC were rested for 4 h in complete RPMI1640 medium
(Life Technologies, Darmstadt, Germany) containing 10% FBS (PAA, Cölbe,
Germany) in a humidiﬁed 5% CO2 atmosphere at 37°C. Afterwards, 10
6
PBMC were used for phenotypic studies. From the remaining cells, CD4+
and CD4− fractions were isolated as described. An aliquot of CD4+ cells was
seeded in a 96-well round bottom plate (Corning, Kaiserslautern, Germany)
and stimulated with anti-CD2/CD3/CD28-coated beads (Miltenyi) at a bead
to cell ratio of 1:2 in complete RPMI1640 medium containing 10% FBS in
humidiﬁed 5% CO2 atmosphere at 37°C. Supernatants (SN) were collected
after 16 h of stimulation.
multiplex cytokine array
Cytokines in SN of CD4+ T cells were measured by ﬂow cytometry using
FlowCytomix (Human Th13-plex, eBioscience, San Diego, CA) according to
the manufacturer’s instructions.
statistical analysis
Data were analyzed with SPSS 20.0 (IBM Corp., Armonk, NY) using the
Wilcoxon signed-rank and Mann–Whitney U-test for continuous variables.
The χ2 tests and Fisher’s exact tests were used to test for differences between
categorical variables. Correlations were assessed by using the Spearman rank
test. Survival was analyzed by the Kaplan–Meier method and tested for dif-
ferences using the log-rank test.
results
study population
Clinicopathological characteristics of patients enrolled in this
study and treated with either vemurafenib (n = 277) or dabrafe-
nib (n = 65) are shown in Table 1 and supplementary Table S1,
available at Annals of Oncology online. While age, sex and
disease stage were similar between patients treated with either
selective BRAFi, lactate dehydrogenase (LDH) levels before
treatment were signiﬁcantly higher in patients receiving vemura-
fenib than dabrafenib (P = 0.034). Pretreatment lymphocyte
counts did not differ signiﬁcantly between both groups. Both
progression-free survival (PFS, 21.3 weeks for vemurafenib
versus 21 weeks for dabrafenib, P = 0.98) and overall survival
(OS) (vemurafenib: 44.1 versus dabrafenib: 46.3 weeks; P = 0.88)
were similar in patients treated with either compound.
vemurafenib but not dabrafenib causes selective
loss of peripheral lymphocytes
As shown in Figure 1A, patients treated with vemurafenib
showed a signiﬁcant decrease in peripheral lymphocytes within
the ﬁrst 12 weeks of treatment (median change: −24.3%,
P < 0.0001) which was not observed in patients treated with dab-
rafenib (Figure 1B, median change: +1.2%, P = 0.72). The
Kaplan–Meier analyses of both cohorts grouped by patients
below the ﬁrst quartile, the median, the third quartile, and
patients above the third quartile showed no association of PFS
or OS with the loss of peripheral lymphocytes (Figure 1C–F). As
shown in supplementary Figure S1A–D, available at Annals of
Oncology online, LDH serum levels negatively correlated with
PFS and OS in patients treated with either selective BRAFi.
However, loss of lymphocytes was not associated with a high
level of LDH before therapy (supplementary Figure S1E and F,
available at Annals of Oncology online) implying that the differ-
ing LDH levels in both groups before treatment did not contrib-
ute to the differential effects of dabrafenib and vemurafenib on
peripheral lymphocytes. We further investigated the effect on
leukocytes by analyzing neutrophil counts in the treated
patients. Both selective BRAFi led to a signiﬁcant decrease in
peripheral neutrophils (vemurafenib: −23%, P < 0.0001; dabrafe-
nib: −29.1%, P < 0.0001, data not shown). In contrast to lympho-
cytes, the change in peripheral neutrophil counts was similar in
both treatment groups (P = 0.26, two-tailed Mann–Whitney test
comparing the median change of neutrophil counts among both
treatment groups). While dabrafenib and vemurafenib both
decreased the number of circulating neutrophils, only vemurafe-
nib-treated patients showed a loss of peripheral lymphocytes.
subset analyses of peripheral lymphocytes
in patients treated with BRAFi
Human peripheral blood lymphocytes consist of three major
subsets: NK cells (5–15%), B cells (5–15%) and T cells (70–
90%). In vemurafenib-treated patients, the most profound loss
of peripheral lymphocytes was in the CD4+ T cell compartment
(Figure 2A). Absolute numbers of peripheral B cells remained
unchanged. CD8+ T cells showed a trend toward decreased
numbers. A signiﬁcant increase in the absolute numbers of
peripheral NK cells was noted (Figure 2A).
frequency and phenotype of peripheral CD4+ T cells
under vemurafenib treatment
As peripheral CD4+ T cell numbers were most severely affected
by vemurafenib, their phenotypical and functional properties
were analyzed in more detail. As shown in Figure 2B, vemurafe-
nib treatment did not increase the frequency of dead T cells
among PBMC, but a signiﬁcant decrease in CD4+ T cells with a
central memory phenotype was observed, while the naїve cell
population concurrently increased (Figure 2C and D).
CD4+ T cells can be subdivided in to several lineages and
distinguished by their cytokine proﬁle [10]. For functional ana-
lysis, we analyzed SN of polyclonal stimulated CD4+ T cells
using multiplex cytokine arrays. As shown in supplementary
Figure S2, available at Annals of Oncology online, a signiﬁcant
decrease in IFN-γ (P < 0.01) in SN from CD4+ T cells obtained
during vemurafenib treatment compared with samples acquired
before treatment was found, pointing to a preferential decrease
in the numbers of type 1 helper T cells (Th1). A similar, also
signiﬁcant, change could be observed for interleukin (IL)-9
(P < 0.05). Levels of IL-2, IL-4, IL-10 and IL-17A remained un-
affected. In summary, our ex vivo data indicate that vemurafenib
alters the frequency, phenotype and function of human peri-
pheral CD4+ T cells.
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discussion
In this study, the impact of two selective BRAFi on the human
peripheral immune system is investigated. While dabrafenib and
vemurafenib showed similar clinical efﬁcacy, only vemurafenib
was found to cause a loss of peripheral lymphocytes. As previ-
ous studies relied on in vitro systems for functional analyses, our
study also presents data on phenotype and function of human
T cells obtained from patients treated with vemurafenib.
Follow-up data from the BRIM-3 (vemurafenib [11]) and
BREAK-3 trial (dabrafenib [12]) showed a median PFS of 6.9
months (∼30 weeks) for vemurafenib and dabrafenib. The
median OS was 18.2 months (∼79.2 weeks) for dabrafenib and
13.6 months (∼59.2 weeks) for vemurafenib. The median PFS
(vemurafenib: 21.3 weeks, dabrafenib: 21.0 weeks) and median
OS (vemurafenib: 44.1 weeks, dabrafenib: 46.3 weeks) were
lower in the patient cohort presented than in these prospective
clinical trials. However, while both BRIM-3 trial and BREAK-3
trial solely enrolled previously untreated patients without active
brain metastases, we included pre-treated patients as well as
patients with active brain metastases into our analyses. Also, the
percentage of patients classiﬁed M1c was lower in both pro-
spective phase III trials (BRIM-3 and BREAK-3: 66%) when
compared with the cohort analyzed in the present study (vemur-
afenib group: 80%, dabrafenib group: 89%). The differences in
PFS and OS observed in our cohort compared with the pro-
spective clinical trials BRIM-3 and BREAK-3 are thus most
likely due to differences in the type of patients included in the
respective studies.
Elevated serum LDH is known to be associated with a worse
prognosis in patients with metastatic melanoma [9]. In the
cohort presented, an association between serum LDH and PFS
as well as OS was found for both selective BRAFi. To our knowl-
edge, associations of pre-therapeutic serum LDH with survival
rates in patients treated with selective BRAFi have not been
reported previously. Clinical response to selective BRAFi seems
to be limited in patients with higher pretreatment serum LDH.
Although a difference in LDH levels could contribute to the
lower PFS and OS in the patient cohort presented, an exact com-
parison was not possible as exact values of serum LDH were not
published for BRIM-3 and BREAK-3 trial, respectively.
Analyzing WBC from a large cohort of patients treated with
selective BRAFi, we found that vemurafenib, but not dabrafenib,
reduces absolute numbers of peripheral lymphocytes. The loss
of peripheral lymphocytes was previously related to disease pro-
gression rather than treatment [13]. In our Kaplan–Meier
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Figure 1. Speciﬁc and common characteristics of selective BRAFi: vemurafenib (A), but not dabrafenib (B), causes a loss of absolute numbers of patients’ lym-
phocytes. Bars indicate medians, whiskers showing interquartile range. However, the Kaplan–Meier analyses of patients’ OS and PFS grouped by patients below
the ﬁrst quartile, the median, the third quartile, and patients above the third quartile showed no association of changes in lymphocyte count and survival for
both selective BRAFi (C–F). Absolute numbers of peripheral lymphocytes per nanoliter are shown (A and B). Each dot represents one individual patient.
Cumulative survival expressed in weeks shown. Patients without an event were censored at last follow-up (C–F).
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Figure 2. Vemurafenib selectively diminishes circulating CD4+ T cells: (A) vemurafenib decreases the number of peripheral CD4+ T cells but increases NK
cell numbers signiﬁcantly while B cells and CD8+ T cells are unaffected. Absolute numbers of cells per nanoliter from 18 independent donors are shown. Each
dot represents one individual patient. *P < 0.05. (B) The frequency of dead cells within the CD4+ gate is not affected by vemurafenib as determined in 10 inde-
pendent donors before and during treatment. (C) However, an increase in the frequency of naïve CD4+ T cells and a decrease in CD4+ T cells with the pheno-
type of central memory (CM) T cells was observed. The frequency of CCR7+CD45RA+ (naïve) and CCR7+CD45RA− (CM) T cells within the CD4+ gate from
10 different donors is shown. **P < 0.01. (D) Representative density plots showing Th cell phenotype before therapy (top row) and during treatment (bottom
row) of one melanoma patient. The frequency of lymphocytes as deﬁned by their forward and side scatter (FS/SS) characteristics as well as the frequency of
CD4+ cells within the lymphocyte gate decreases during treatment (left panel). In addition, the frequency of naïve CD4+ T cells increases while CM CD4+ T
cells are reduced within peripheral lymphocytes during treatment (middle panel). However, no increase in the percentage of dead CD4+ T cells can be observed
(right panel, MFI of aqua viability dye shown).
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analyses, no association between loss of peripheral lymphocytes
and PFS or OS was found. A decrease in peripheral lymphocytes
is therefore associated with BRAFi therapy and depends on the
speciﬁc BRAFi rather than disease progression. While only
vemurafenib caused a loss of peripheral lymphocytes, both
selective BRAFi led to a signiﬁcant but similar decrease in peri-
pheral neutrophils. Despite similar clinical efﬁcacy as dabrafe-
nib, vemurafenib shows a previously unrecognized speciﬁc and
selective effect on human peripheral lymphocyte populations.
Selective BRAFi induce paradoxical activation of the MAPK
pathway in BRAF wild-type cells which could contribute to the
functional and phenotypic changes in CD4+ T cells observed
during vemurafenib treatment [14]. In vitro, 50 μM vemurafenib
was shown to lead to increased levels of pERK1/2 and pp38 in
human T cells [4]. In contrast, Callahan et al. [15] reported
increased activation of ERK1/2 in monocytes harboring an
NRAS G12R mutation from a patient receiving vemurafenib,
while no elevated levels of pERK1/2 were observed in the re-
spective lymphocytes. So far, evidence of paradoxical activation
of the MAPK pathway in human lymphocytes by selective
BRAFi is limited to high doses used in in vitro studies.
Paradoxical activation could however be one explanation for the
changes in frequency, phenotype and function of human lym-
phocytes observed in our study.
Recently, Hong et al. [7] carried out an extensive analysis of
PBMC obtained from patients treated with dabrafenib and found
no changes in the absolute numbers of lymphocyte subsets (T, B
and NK cells) or ex vivo functionality of T cells. We observed a
decline in peripheral CD4+ T cells and an increase in circulating
NK cell numbers in patients treated with vemurafenib. Decreased
survival as well as changes in the compartmental distribution of
CD4+ T cell subsets are possible explanations. Survival of CD4+
T cells seems to be unaffected by vemurafenib treatment as no
increased frequency of apoptotic CD4+ was observed, a ﬁnding
consistent with previous in vitro studies [4]. An intriguing pos-
sible explanation would be that peripheral lymphocytes progres-
sively inﬁltrate tumor tissue in response to vemurafenib.
Increased inﬁltration of melanoma metastases by both CD8+ and
CD4+ T cells has been reported in patients receiving vemurafenib
but also for patients treated with dabrafenib [6]. As dabrafenib
does not change the number of CD4+ and CD8+ T cells in the
blood of treated patients [7], we believe a shift of cells from blood
into tumor tissue is an unlikely mechanism for the loss of periph-
eral CD4+ cells observed in our study. Migration into secondary
lymphoid tissue could be another explanation for the loss of per-
ipheral CD4+ cells observed in our study. CCL21 is a major
chemoattractant for CD4+ T cells [16]. Since activation of the
MAPK pathway results in increased secretion of CCL21 by
lymphatic endothelial cells [16], vemurafenib could induce migra-
tion into secondary lymphoid organs, but the effect of vemurafe-
nib on endothelial cells remains to be determined. The decline in
circulating CD4+ T cells appears not to be due to decreased sur-
vival but to a change in the compartmental distribution of CD4+
T cells. However, the reason for the decrease in circulating CD4+
T cells under therapy with vemurafenib remains unclear and has
to be explored in future studies.
Despite a decrease in absolute numbers, we found phenotypic
and functional changes in circulating CD4+ T cells in patients
treated with vemurafenib. While the proportion of peripheral
naїve CD4+CCR7+CD45RA+ T cells increased signiﬁcantly, a
concomitant decrease in the frequency of central memory (CM,
CD4+CCR7+CD45RA−) T cells was noted [17]. Expansion of
naїve CD4+ T cells was noted in patients with systemic lupus ery-
thematosus receiving an IL-6 receptor-blocking antibody [18].
Since silencing mutated BRAF also leads to decreased secretion of
IL-6 by melanoma cells [19], vemurafenib might cause an in-
crease in circulating naїve CD4+ cells by blocking IL-6 production
from melanoma cells. Compared with memory cells, naїve CD4+
T cells only produce low levels of effector cytokines [17]. Thus,
the decrease in interferon-γ (IFN-γ) and IL-9 production by bulk
CD4+ T cells from patients under vemurafenib treatment could
be explained by the increased proportion of naїve CD4+ T cells.
Since IFN-γ and IL-9 have been reported to play an important
role in cancer immunosurveillance [20, 21], vemurafenib treat-
ment of melanoma patients might have a dampening effect on
anti-tumor immunity.
In summary, our data show unexpected differences between
vemurafenib- and dabrafenib-treated patients. Both agents showed
similar clinical efﬁcacy with comparable PFS and OS which in-
versely correlated with pre-therapeutic serum LDH levels. The
inﬂuence on patients’ lymphocyte populations however differed
signiﬁcantly, with vemurafenib but not dabrafenib leading to a loss
of peripheral lymphocytes. Vemurafenib further altered the fre-
quency, function and phenotype of CD4+ T cells in patients with
advanced melanoma. We believe our ﬁndings highlight that select-
ive BRAFi need to be assessed individually for immunomodula-
tory effects, in particular, when planning combination therapies
with other agents, such as immunotherapeutic substances.
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